Gedea starts clinical study

Swedish Medical Products Agency and Ethics Committee have announced that they approve Gedea’s first clinical study. The study is an important step prior to CE marking ofpHyph, which is a completely new type of treatment for vaginal infection. pHyph is expected to be able to treat both vaginal fungal infections and bacterial vaginosis and may become the first product on the market for treatment of both types of infection.